PAX6

Across TCGA pan-cancer cohorts, PAX6 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated PAX6 data layer compared with 2 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher PAX6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAX6 expression acts as an unfavorable survival marker, although some lineages such as KIRC and PAAD show a favorable association.

MESO, ACC, and SCLC are the cancer types where PAX6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	All	0.274	0.451	<.001	108	view →
ACC	DFS	Median	II,III,IV	0.223	0.603	<.001	63	view →
SCLC	DFS	Tertile	IV	0.110	0.446	.010	36	view →
KIRC	DFS	Quartile	All	0.687	0.388	.001	34	view →
DLBC	DFS	Median	III,IV	0.294	0.984	.003	29	view →
BLCA	OS	Median	All	0.362	0.483	.011	20	view →
PAAD	DFS	Quartile	All	0.481	0.181	.009	15	view →
HNSC	DFS	Median	IV	0.644	0.506	.020	14	view →
KICH	OS	Quartile	II,III,IV	0.358	1.000	.006	13	view →
ESCA	DFS	Quartile	All	0.361	0.609	.006	12	view →
BRCA	DFS	Tertile	IV	0.365	0.704	.027	9	view →
STAD	DFS	Median	III,IV	0.572	0.286	.029	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

PAX6–MESO (DFS)

Open the MESO breakdown →